Table 3. Association of IL-37 expression in OSCC with patients’ clinicopathological characteristics (n = 60).

	Total n	Negative n	Weak n	Strong n	P value
		(percentage)	(percentage)	(percentage)
Gender
Female	44	8 (18.2%)	20 (45.4%)	16 (36.4%)	0.468
Male	16	2 (12.5%)	5 (31.3%)	10 (56.2%)
Age
<60	31	6 (19.4%)	11 (35.5%)	14 (45.2%)	0.349
≥60	29	4 (13.8%)	14 (48.3%)	11 (37.9%)
Smoking status
Smoker	35	5 (14.3%)	16 (45.7%)	14 (40.0%)	0.636
Nonsmoker	25	5 (20.0%)	9 (36.0%)	11 (44.0%)
Differentiation
Well	34	5 (14.7%)	14 (41.2%)	14 (44.1%)	0.350
Medium/Poor	26	5 (19.2%)	11 (42.3%)	10 (38.5%)
Tumor stage
T1–T2	42	8 (19.0%)	20 (47.6%)	14 (33.3%)	0.365
T3–T4	18	2 (11.1%)	5 (27.8%)	11 (61.1%)
Nodal stage
N0	30	3 (10.0%)	12 (40.0%)	15 (50.0%)	0.006
N1–Nx	30	7 (23.3%)	13 (43.3%)	12 (33.3%)
Clinical TNM stage
I	9	0 (0.0%)	4 (44.4%)	5 (55.6%)	0.082
II	12	3 (25.0%)	5 (41.7%)	4 (33.3%)
III	31	5 (16.1%)	15 (48.4%)	11 (35.5%)
IV	8	2 (25.0%)	1 (12.5%)	5 (62.5%)